Vinflunine in Advanced Transitional Cell Cancer of the Urothelial Tract: A Potential Option for Maintenance Therapy? A Case Series

Raffaella Palumbo, Luca Licata, Federico Sottotetti, Barbara Tagliaferri, Emma Pozzi, Cristina Teragni, Erica Quaquarini, Antonio Bernardo

Research output: Contribution to journalArticle

Abstract

INTRODUCTION: Vinflunine is a microtubule inhibitor approved in Europe as second-line treatment of advanced transitional cell cancer of the urothelium (TCCU). The inability to continue with a first-line platinum-based regimen beyond 6 cycles suggested investigating the use of vinflunine as switch maintenance therapy in patients with response or stable disease after first-line therapy.

METHODS: Patients with advanced TCCU and documented disease control after 3-6 cycles of first-line platinum-based chemotherapy received vinflunine maintenance therapy within 6 weeks of the last cycle. Our analysis aimed to examine the performance of vinflunine in terms of activity and safety in such a patient population.

RESULTS: 28 consecutive patients were studied. After a median follow-up of 25 months, vinflunine was associated with a median progression-free survival of 9 months (range 4 to > 16 months) and a disease control rate of 64%; median overall survival was not reached. Treatment was well tolerated, with no unexpected safety events. The most common adverse events of grade ≥ 3 were neutropenia (21%) and constipation (14%); no toxicity-related death occurred.

CONCLUSIONS: Our results suggest that vinflunine may be a suitable maintenance treatment option for TCCU patients who received a maximum of 6 cycles of platinum-based chemotherapy commonly used as first-line treatment.

Original languageEnglish
Pages (from-to)8-13
Number of pages6
JournalOncology Research and Treatment
Volume41
Issue number1-2
DOIs
Publication statusPublished - 2018

Fingerprint

Urothelium
Platinum
Neoplasms
Therapeutics
Safety
Drug Therapy
Constipation
vinflunine
Neutropenia
Microtubules
Disease-Free Survival
Survival
Population

Cite this

Vinflunine in Advanced Transitional Cell Cancer of the Urothelial Tract : A Potential Option for Maintenance Therapy? A Case Series. / Palumbo, Raffaella; Licata, Luca; Sottotetti, Federico; Tagliaferri, Barbara; Pozzi, Emma; Teragni, Cristina; Quaquarini, Erica; Bernardo, Antonio.

In: Oncology Research and Treatment, Vol. 41, No. 1-2, 2018, p. 8-13.

Research output: Contribution to journalArticle

@article{600c4155f76d4af2bd219af818b16c14,
title = "Vinflunine in Advanced Transitional Cell Cancer of the Urothelial Tract: A Potential Option for Maintenance Therapy? A Case Series",
abstract = "INTRODUCTION: Vinflunine is a microtubule inhibitor approved in Europe as second-line treatment of advanced transitional cell cancer of the urothelium (TCCU). The inability to continue with a first-line platinum-based regimen beyond 6 cycles suggested investigating the use of vinflunine as switch maintenance therapy in patients with response or stable disease after first-line therapy.METHODS: Patients with advanced TCCU and documented disease control after 3-6 cycles of first-line platinum-based chemotherapy received vinflunine maintenance therapy within 6 weeks of the last cycle. Our analysis aimed to examine the performance of vinflunine in terms of activity and safety in such a patient population.RESULTS: 28 consecutive patients were studied. After a median follow-up of 25 months, vinflunine was associated with a median progression-free survival of 9 months (range 4 to > 16 months) and a disease control rate of 64{\%}; median overall survival was not reached. Treatment was well tolerated, with no unexpected safety events. The most common adverse events of grade ≥ 3 were neutropenia (21{\%}) and constipation (14{\%}); no toxicity-related death occurred.CONCLUSIONS: Our results suggest that vinflunine may be a suitable maintenance treatment option for TCCU patients who received a maximum of 6 cycles of platinum-based chemotherapy commonly used as first-line treatment.",
author = "Raffaella Palumbo and Luca Licata and Federico Sottotetti and Barbara Tagliaferri and Emma Pozzi and Cristina Teragni and Erica Quaquarini and Antonio Bernardo",
note = "{\circledC} 2018 S. Karger GmbH, Freiburg.",
year = "2018",
doi = "10.1159/000481098",
language = "English",
volume = "41",
pages = "8--13",
journal = "Oncology Research and Treatment",
issn = "2296-5270",
publisher = "S. Karger AG",
number = "1-2",

}

TY - JOUR

T1 - Vinflunine in Advanced Transitional Cell Cancer of the Urothelial Tract

T2 - A Potential Option for Maintenance Therapy? A Case Series

AU - Palumbo, Raffaella

AU - Licata, Luca

AU - Sottotetti, Federico

AU - Tagliaferri, Barbara

AU - Pozzi, Emma

AU - Teragni, Cristina

AU - Quaquarini, Erica

AU - Bernardo, Antonio

N1 - © 2018 S. Karger GmbH, Freiburg.

PY - 2018

Y1 - 2018

N2 - INTRODUCTION: Vinflunine is a microtubule inhibitor approved in Europe as second-line treatment of advanced transitional cell cancer of the urothelium (TCCU). The inability to continue with a first-line platinum-based regimen beyond 6 cycles suggested investigating the use of vinflunine as switch maintenance therapy in patients with response or stable disease after first-line therapy.METHODS: Patients with advanced TCCU and documented disease control after 3-6 cycles of first-line platinum-based chemotherapy received vinflunine maintenance therapy within 6 weeks of the last cycle. Our analysis aimed to examine the performance of vinflunine in terms of activity and safety in such a patient population.RESULTS: 28 consecutive patients were studied. After a median follow-up of 25 months, vinflunine was associated with a median progression-free survival of 9 months (range 4 to > 16 months) and a disease control rate of 64%; median overall survival was not reached. Treatment was well tolerated, with no unexpected safety events. The most common adverse events of grade ≥ 3 were neutropenia (21%) and constipation (14%); no toxicity-related death occurred.CONCLUSIONS: Our results suggest that vinflunine may be a suitable maintenance treatment option for TCCU patients who received a maximum of 6 cycles of platinum-based chemotherapy commonly used as first-line treatment.

AB - INTRODUCTION: Vinflunine is a microtubule inhibitor approved in Europe as second-line treatment of advanced transitional cell cancer of the urothelium (TCCU). The inability to continue with a first-line platinum-based regimen beyond 6 cycles suggested investigating the use of vinflunine as switch maintenance therapy in patients with response or stable disease after first-line therapy.METHODS: Patients with advanced TCCU and documented disease control after 3-6 cycles of first-line platinum-based chemotherapy received vinflunine maintenance therapy within 6 weeks of the last cycle. Our analysis aimed to examine the performance of vinflunine in terms of activity and safety in such a patient population.RESULTS: 28 consecutive patients were studied. After a median follow-up of 25 months, vinflunine was associated with a median progression-free survival of 9 months (range 4 to > 16 months) and a disease control rate of 64%; median overall survival was not reached. Treatment was well tolerated, with no unexpected safety events. The most common adverse events of grade ≥ 3 were neutropenia (21%) and constipation (14%); no toxicity-related death occurred.CONCLUSIONS: Our results suggest that vinflunine may be a suitable maintenance treatment option for TCCU patients who received a maximum of 6 cycles of platinum-based chemotherapy commonly used as first-line treatment.

U2 - 10.1159/000481098

DO - 10.1159/000481098

M3 - Article

C2 - 29402855

VL - 41

SP - 8

EP - 13

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

SN - 2296-5270

IS - 1-2

ER -